Homologous Recombination Inquiry Through Ovarian Malignancy Investigations
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 700
Summary
- Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Retrospective
Participation Requirements
- Age
- Between 20 years and 125 years
- Gender
- Only males
Description
In this study, investigators plan to clarify the frequency of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer). And investigators will also investigate whether HRD-positive ovarian cancer patients show ...
In this study, investigators plan to clarify the frequency of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer). And investigators will also investigate whether HRD-positive ovarian cancer patients show the clinical characteristics of highly platinum-sensitivity and good prognosis, comparing to HRD-negative ovarian cancer patients. In addition, it is planned to investigate any association between Progression Free Survival (PFS) / Platinum-Sensitivity and germline mutation in Breast Cancer Susceptibility Gene (BRCA1/2 gene) in ovarian cancer patients who can provide the patients' gBRCA1/2 gene information for this study.
Tracking Information
- NCT #
- NCT03159572
- Collaborators
- Department of Obstetrics and Gynecology, School of Medicine, Niigata University
- Japanese Gynecologic Oncology Group (JGOG)
- Tohoku Medical Megabank Organization(ToMMo)
- Investigators
- Study Chair: Takayuki Enomoto, MD, Ph.D Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences
Get Well Soon